CA2670892C — Substituted diazepan compounds as orexin receptor antagonists
Assigned to Merck Sharp and Dohme LLC · Expires 2013-08-13 · 13y expired
What this patent protects
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which may be used in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also…
USPTO Abstract
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which may be used in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds. These compositions may be used in the prevention or treatment of such diseases in which orexin receptors are involved.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.